Method of treating and/or preventing cancers using Sartans and/or Statins to modulate VDR, and/or PPAR, and/or GCR and/or CB1 receptors; in conjunction with certain bacteriostatic antibiotics

摘要

This invention is a method of killing the stealthy intra-cellular bacteria which are key to the pathogenesis Cancers. These very tiny L-form Cell-Wall-Deficient (CWD) antibiotic-resistant bacteria live within the cytoplasm of cells, including the phagocytic cells (e.g. monocytes, macrophages, lymphocytes, neutrophils and polymorphonuclear cells) of the immune system itself. The cellular proliferation in Cancer is catalysed the action of the same tiny L-form bacteria. They cause the cell nucleus to release mRNA signaling the Th1 cytokine cascade without the need for conventional signaling via, for example, CD4+T -Lymphocytes. Some of these Cytokines and Chemokines, including, without limitation, Cellular Adhesion Molecule (CAM), create the environment which allows the cellular proliferation to start, and then allows the cancerous growth to gain a foothold in the body. Killing these stealthy pathogens removes the environment needed to initiate and feed the cellular proliferation commonly called ‘Cancer’. This invention achieves its objective partly by reducing the ability of these tiny L-form, intra-phagocytic bacteria to translate proteins within their 70S Ribosome. The 30S and 50S subunits of the bacterial ribosome are targeted both individually and collectively. Further, this invention activates the innate immune system with agonist(s) for the VDR Nuclear Receptor, and modulates the availability of endogenous ligands to the PPAR, GCR and CB1 receptors, conditioning the immune system to more easily recognize and kill these tiny bacterial pathogens.

主权项

1. A method for reducing risk of an inflammatory-induced disease caused by intra-phagocytic prokaryotic pathogens, wherein the inflammatory-induced disease is selected from the group consisting of Bladder Cancer, Breast Cancer, Colorectal Cancer, Gastric Cancer, Liver Cancer, Lung Cancer, Pancreatic Cancer, Prostate Cancer, and Thyroid Cancer; comprising administering to a subject in need thereof a therapeutically effective amount of Olmesartan or Olmesartan medoxomil, together with one or more antibiotics capable of inhibiting bacterial protein synthesis by inhibiting the intra-phagocytic prokaryotic 70S-bacterial-ribosome to treat intra-phagocytic prokaryotic pathogens and reduce the risk of an inflammatory-induced disease, wherein the Olmesartan or Olmesartan medoxomil is administered by semi-continuous or intermittent administration in such a way that the Olmesartan or Olmesartan medoxomil has a concentration in the subject's bloodstream that is constrained from falling below 30% of its peak value.